Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

Open access
Norquist, Barbara M., Brady, Mark F., Harrell, Maria I., Walsh, Tom, Lee, Ming K., Gulsuner, Suleyman, Bernards, Sarah S., Casadei, Silvia, Burger, Robert A., Tewari, Krishnansu S., Backes, Floor, Mannel, Robert S., Glaser, Gretchen, Bailey, Cheryl, Rubin, Stephen, Soper, John, Lankes, Heather A., Ramirez, Nilsa C., King, Mary Claire, Birrer, Michael J., Swisher, Elizabeth M. · 2018 · Clinical Cancer Research

Abstract

Purpose: We hypothesized that mutations in homologous recombination repair (HRR) genes beyond BRCA1 and BRCA2 improve outcomes for ovarian carcinoma patients treated with platinum therapy and would impact the relative benefit of adding prolonged bevacizumab. Experimental Design: We sequenced DNA from blood and/or neoplasm from 1,195 women enrolled in GOG-0218, a randomized phase III trial in advanced ovarian carcinoma of bevacizumab added to carboplatin and paclitaxel. Defects in HRR were defined as damaging mutations in 16 genes. Proportional hazards models were used to estimate relative hazards for progression-free survival (PFS) and overall survival (OS). Results: Of 1,195 women with ovarian carcinoma, HRR mutations were identified in 307 (25.7%). Adjusted hazards for progression and death compared with those without mutations were lower for women with non-BRCA HRR mutations [HR = 0.73; 95% confidence interval (CI), 0.57–0.94; P = 0.01 for PFS; HR = 0.67; 95% CI, 0.50–0.90; P = 0.007 for OS] and BRCA1 mutations (HR = 0.80; 95% CI, 0.66–0.97; P = 0.02 for PFS; HR = 0.74; 95% CI, 0.59–0.94; P = 0.01 for OS) and were lowest for BRCA2 mutations (HR = 0.52; 95% CI, 0.40–0.67; P < 0.0001 for PFS; HR = 0.36; 95% CI, 0.25–0.53; P < 0.0001 for OS). A test of interaction showed no difference in the effect of bevacizumab on PFS between cases with and without mutations. Conclusions: HRR mutations, including non-BRCA genes, significantly prolong PFS and OS in ovarian carcinoma and should be stratified for in clinical trials. The benefit of adding bevacizumab was not significantly modified by mutation status. Clin Cancer Res; 24(4); 777–83. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-1327

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 230

Metadata

Authors
Norquist, B. M., Brady, M. F., Harrell, M. I., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Burger, R. A., Tewari, K. S., Backes, F., Mannel, R. S., Glaser, G., Bailey, C., Rubin, S., Soper, J., Lankes, H. A., Ramirez, N. C., King, M. C., Birrer, M. J., & Swisher, E. M.
Venue
Clinical Cancer Research
Published
2018-02-14
Volume
24
Issue
4
Pages
777-783
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2772338061
Cited by
230
References
3
FWCI
18.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1327
The paper
Norquist, B. M., Brady, M. F., Harrell, M. I., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Burger, R. A., Tewari, K. S., Backes, F., Mannel, R. S., Glaser, G., Bailey, C., Rubin, S., Soper, J., Lankes, H. A., Ramirez, N. C., King, M. C., . . . Swisher, E. M. (2018). Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1327

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.